Core Viewpoint - The company is implementing a Co-Chief Executive Officer (Co-CEO) system to enhance its global strategy and operational efficiency, with Dr. Andrea Wang-Gillam appointed as Co-CEO effective November 12, 2025 [1] Group 1: Leadership Changes - Dr. Andrea Wang-Gillam, currently the Chief Medical Officer, has been appointed as Co-CEO, bringing over 20 years of experience in oncology and a deep understanding of international clinical trial regulations and commercialization [1] - The introduction of the Co-CEO system is part of the company's strategy to create a collaborative model that integrates global strategic oversight with regional operational execution [1] Group 2: Strategic Implications - This leadership adjustment is a significant step in advancing the company's globalization strategy, aimed at creating greater value for shareholders [1]
加科思-B(01167)委任王宜为联席首席执行官